Nachrichten zur Biogen Inc. Aktie

Biotech Stock Roundup: BIIBs Q4 Results, CBAY Up on GILDs Acquisition & Other Updates

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.…

Biogen: Kursziel reduziert

Milwaukee (www.aktiencheck.de) - Rating-Update: Brian Skorney, Analyst von Robert W. Baird, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Biogen: Kurszielreduzierung

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von J.P. Morgan Securities bewerten die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Biogen: Q4-Zahlen fallen gemischt aus - Aktienanalyse

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Oppenheimer: Die Analysten von Oppenheimer senken in einer aktuellen Aktienanalyse ihr Kursziel für die Aktie…

Biogen: Gewinnprognose in Q4 deutlich verfehlt - Kurszielsenkung - Aktienanalyse

Minneapolis (www.aktiencheck.de) - Biogen-Aktienanalyse von Piper Sandler: Die Analysten von Piper Sandler stufen in einer aktuellen Aktienanalyse die Aktie von Biogen…

Biogen: Zu viele Unwägbarkeiten - Aktienanalyse

San Francisco (www.aktiencheck.de) - Biogen-Aktienanalyse von Wells Fargo Advisors: Mohit Bansal, Analyst von Wells Fargo Advisors, stuft in einer aktuellen Aktienanalyse…

Biogens Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

…

Stocks making the biggest moves midday: JetBlue Airways, Shopify, Biogen and more

These are the stocks posting the largest moves in midday trading.…

Weniger Multiple-Sklerose-Geschäft: Biogen-Umsatz fällt - Alzheimer im Fokus

CAMBRIDGE (dpa-AFX) - Schwächere Geschäfte mit Medikamenten gegen Multiple Sklerose haben 2023 auf den Umsatz von…

Weniger Multiple-Sklerose-Geschäft: Biogen-Umsatz fällt - Alzheimer im Fokus

CAMBRIDGE (dpa-AFX) - Schwächere Geschäfte mit Medikamenten gegen Multiple Sklerose haben 2023 auf den Umsatz von Biogen gedrückt. Der…

Biogen Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Biogen (BIIB) Q4 2023 Earnings Call Transcript

BIIB earnings call for the period ending December 31, 2023.…

Biogen fourth-quarter profit misses on Aduhelm exit costs By Reuters

Biogen fourth-quarter profit misses on Aduhelm exit costs…

Biogen falls as earnings, revenue misses consensus By Investing.com

Biogen falls as earnings, revenue misses consensus…

Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

The results come amid the rollout of Biogen and Eisais Leqembi, the first drug found to slow the progression of…

Biogen earnings missed by $0.23, revenue fell short of estimates By Investing.com

Biogen earnings missed by $0.23, revenue fell short of estimates…

Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript

…

Eilt: Biotech Aktientip kündigt bahnbrechende News an. Neuer 312% Biotech Hot Stock nach 134.452 mit Biogen ($BIIB)

London (www.aktiencheck.de, Anzeige) EinschätzungStrong OutperformerKurszieleKursziel 12M: 2,50 EUR Kurschance: 194% Kursziel 24M: 3,50 EUR Kurschance: 312%StammdatenISIN: GB00BM9XQ619 WKN: A3DTUQ Ticker: T9G.HMKursdatenKurs: 0,850 EUR 52W Hoch: 1,630 EUR 52W…

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.…

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has…

Aktie von Biogen heute am Aktienmarkt gefragt (226,3852 €)

Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Biogen gegenwärtig etwas fester. Das Wertpapier kostete zuletzt 243,93 US-Dollar. Das Wertpapier von…

Biogen Q4 2023 Earnings Preview

…

AptarGroup (ATR) Inks Deal to Create Digital Health Solutions

AptarGroup (ATR) enters an enterprise agreement with Biogen to create digital health solutions for neurological and rare diseases.…

Earnings week ahead: Coca-Cola, Cisco, Shopify, Roku, Biogen and more

…

Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?

Biogens (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis…

Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023

Stockholm, Sweden, February 6, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report…

Biogen (BIIB) to Stop Selling Alzheimers Disease Drug Aduhelm

Biogen (BIIB) aims to build a leading Alzheimers disease franchise with the new drug Leqembi. The company quits commercializing the…

Biogen drops controversial Alzheimers drug Aduhelm to focus on Leqembi, experimental treatments

Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety…

Biogen verabschiedet sich endgültig von umstrittenenem Alzheimer-Wirkstoff

CAMBRIDGE (dpa-AFX) - Biogen zieht aus dem Flop mit dem umstrittenen Alzheimer-Medikament Aduhelm Konsequenzen: Der…

Biogen verabschiedet sich endgültig von umstrittenenem Alzheimer-Wirkstoff

CAMBRIDGE (dpa-AFX) - Biogen zieht aus dem Flop mit dem umstrittenen Alzheimer-Medikament Aduhelm Konsequenzen: Der US-Biotechkonzern stellt die Forschung an…

Biogen to discontinue development of older Alzheimers drug Aduhelm By Reuters

Biogen to discontinue development of older Alzheimers drug Aduhelm…

Biogen halts development of controversial Alzheimer’s drug

…

Biogen, Eisai, And Eli Lilly: The Potential Pitfalls Of Anti-Amyloid Antibody Drugs

…

Denalis (DNLI) Pipeline Progresses Despite Stiff Competition

Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners…

Biogen downgraded at UBS as Leqembi ramp progressing slower than expected By Investing.com

Biogen downgraded at UBS as Leqembi ramp progressing slower than expected…

Eisai, Biogen file for EU marketing authorization of Alzheimers drug

…

2 Low-Priced Gene Therapy Stocks to Speculate On

Stocks Analysis by MarketBeat.com (Jea Yu) covering: Novartis AG, Vertex Pharmaceuticals Inc, Biogen Inc, Pfizer Inc. Read MarketBeat.com (Jea Yu)s…

Biogen, Eisai win China approval for Alzheimers drug

…

Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024

…

Former Biogen CEO Michel Vounatsos Joins Quris-AI Board

Former Biogen CEO Michel Vounatsos Joins Quris-AI Board; Yossi Ben Amram Appointed President as BioAI Innovator Continues to Expand…

Eilt: Sensationeller Durchbruch im Kampf gegen den Hautkrebs. 279% Biotech Hot Stock nach 134.452% mit Biogen ($BIIB)

London (www.aktiencheck.de, Anzeige) EinschätzungStrong OutperformerKurszieleKursziel 12M: 1,50 EUR Kurschance: 127% Kursziel 24M: 2,50 EUR Kurschance: 279%StammdatenISIN: GB00BM9XQ619 WKN: A3DTUQ Ticker: T9G.HMKursdatenKurs: 0,660 EUR 52W Hoch: 1,630 EUR 52W…

Biogen value creation to be unlocked, says Cantor Fitzgerald By Investing.com

Biogen value creation to be unlocked, says Cantor Fitzgerald…

Europe revokes approvals for generics of Biogens multiple sclerosis drug Tecfidera

…

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission…

Oppenheimer raises Biogen price target on growing investor confidence By Investing.com

Oppenheimer raises Biogen price target on growing investor confidence…

Biogens (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU

Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreichs ataxia…

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products…

Biogen, Sage launch depression therapy in the U.S.

…

Biogen: Ausblick für Lecanemab konservativer - Aktienanalyse

St. Louis (www.aktiencheck.de) - Biogen-Aktienanalyse von Stifel: Die Analysten von Stifel senken in einer aktuellen Aktienanalyse ihr Kursziel für die Aktie…

dpa-AFX ProFeed